Over 30 years ago [1], the existence of antigenic groups of RSV infection. Thus, we revisited their observations and used the cotton rat to assess the efficacy of RSVIg and of monosperespiratory syncytial virus (RSV) was suggested by the observation that monospecific antiserum raised in ferrets largely cific cotton rat antisera in preventing group B pulmonary infection. neutralized most, but not all, heterologous strains. One strain in particular, designated 18537 (and later shown to be the Materials and Methods prototype of group B strains), showed very little antigenic relationship to most other strains as measured by an in vitro neutral- against group B viruses might be questioned in view of the pared with those of control groups using the 2-tailed Student's t
Over 30 years ago [1] , the existence of antigenic groups of RSV infection. Thus, we revisited their observations and used the cotton rat to assess the efficacy of RSVIg and of monosperespiratory syncytial virus (RSV) was suggested by the observation that monospecific antiserum raised in ferrets largely cific cotton rat antisera in preventing group B pulmonary infection. neutralized most, but not all, heterologous strains. One strain in particular, designated 18537 (and later shown to be the Materials and Methods prototype of group B strains), showed very little antigenic relationship to most other strains as measured by an in vitro neutralOutbred cotton rats (Sigmodon fulviventer) were obtained from ization assay. Several years elapsed before the more sensitive a colony maintained at Virion Systems. Two prototype strains of technology of monoclonal antibodies allowed more precise RSV were used: Long, a group A strain (RSV/A; American Type Culture Collection, Rockville, MD), and 18537, a group B strain characterization of strain differences. RSV strains are now rou-(RSV/B; Dept. of Pediatrics, Uniformed Services University of tinely typed using a panel of monoclonal antibodies and asthe Health Sciences). Stocks of these viruses were grown in HEpsigned to antigenic groups (A and B) and subgroups (e.g., A1-2 cells and contained 10 7 and 10 6 pfu/mL, respectively. Serum A4). activity against homologous virus (1:427) and low activity shown significant antigenic evolution over the past four decades. Indeed, the ability of RSVIg obtained from plasma doagainst heterologous RSV/B (1:117). Similarly, RSV/B antiserum had high activity against homologous virus (1:1126) and nors and thus preferentially reflecting antigenic characteristics of contemporaneous strains to neutralize prototypical A and B lower activity against heterologous RSV/A (1:246). However, its activity against heterologous virus was more than twice that groups suggests that antigenic evolution is not important for the survival of RSV, an assertion further supported by animal of RSV/A antiserum (1:246 vs. 1:117).
These results were reflected in in vivo challenge experiments studies showing that priming with Long strain confers solid immunity against contemporaneous group A virus [9] . (figure 1). RSV/A antiserum effected a 40-fold reduction in RSV/A pulmonary replication (P õ .001) but only a 5-fold reduction in RSV/B (not significant). Similarly, RSV/B antiserum effected a 40-fold reduction in RSV/B replication (P õ .005) and a 15-fold reduction in RSV/A (P õ .005).
RSVIg had far higher titers against both RSV/A (1:15,435) and RSV/B (1:4362), reflecting both the higher IgG concentration (5% vs. Ç1% in cotton rat serum) and the effect of selecting only plasma donors with high RSV antibody titers.
The in vivo efficacy of RSVIg against RSV/A has been described [8] and was not repeated in these experiments. Efficacy against RSV/B was tested at two challenge doses, 10 3 and 10 2 pfu/animal, thought to approximate those likely to occur in natural RSV infection. RSVIg provided significant protection at both doses (figure 2, P õ .001 and õ .005, respectively).
Discussion
The clinical and epidemiologic significance of RSV groups remains unclear. Strain 18537 (group B) was isolated from a volves simultaneous circulation of both groups, and neither has Concise Communications JID 1997; 175 (April) In contrast, influenza viruses have continual antigenic drift antiserum to group B was more effective against homologous virus than was antiserum to group A. The first two hypotheses and periodic antigenic shift, resulting in contemporary strains scarcely related to earlier ones. The capacity of influenza virus remain plausible, however, and we are not currently able to determine whether one is more influential than the other. The to mutate quickly appears to be driven by a virus-host interaction that induces lasting immunity to homologous virus. That ability of RSVIg to protect against group B virus, in light of the observation that homotypic antiserum (cotton rat) against is, infection by 1 strain of influenza virus induces long-term resistance to reinfection and apparently the homologous strain group A virus does not afford heterotypic protection, suggests that the anti-B activity of RSVIg derives from the broad reperinduces life-long protection against clinical illness. Influenza is a highly contagious disease that affects most of the population toire of anti-B antibodies that one would anticipate in a preparation of IgG reflecting the antigenic experience of thousands of during an epidemic. Therefore, the strategy by which influenza ''stays in business'' is to mutate continually. The more antigenplasma donors. The fact that the current studies in the cotton rat, which has ically diverse mutants then have a selective advantage in reinfecting a population with ''herd immunity'' to the parent strains been a highly accurate model of passive RSV immunoprophylaxis, showed RSVIg to be effective against group B and group of virus. The mutability of influenza is enhanced by a multisegmented genome that is highly prone to reassortment with other A infections suggests that RSVIg has broad protective capability. strains.
RSV, on the other hand, contains a single segment of RNA that does not facilitate major antigenic evolution. Like influ-
